The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE.

Yusuke KimuraRena KanekoYuichiro Yano Kentaro Hirao Takashi IkeharaHidenari NagaiYuzuru Sato Yoshinori Igarashi

Published in: Asian Pacific journal of cancer prevention : APJCP (2020)

With an array of therapeutic options currently available, it is important to determine the efficacy of different multimodal strategies, such as sorafenib combined TACE, for patients with unresectable HCC.

Keyphrases

high resolution
pain management
high throughput
liver metastases
squamous cell carcinoma
high density
mass spectrometry